CardioKine

Acquired by Cornerstone Therapeutics
Developed lixivaptan for hyponatremia treatment.

F-Prime Team

Sector

Life Sciences

Category

Therapeutics

Location

Philadelphia, PA

Initial Investment

2006
Developed lixivaptan for hyponatremia treatment.

CardioKine is a pharmaceutical company focused on the development of lixivaptan, an oral compound under development for the potential treatment of hyponatremia in patients with congestive heart failure. CardioKine was acquired by Cornerstone Therapeutics.